HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $290

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $270 to $290.